Floatz logo

Tas-102

GIST

AEterna ZentarisunclassifiedPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the GIST cohort.

Asset / SponsorPhaseRating
Regorafenib
Institut Bergonié
Phase 4BBB
Avapritinib
Blueprint Medicines Corporation
Phase 3BB
Her-2 Vaccine
Robert Wesolowski
Phase 1CC
Perifosine
AEterna Zentaris
Phase 1CC
ALMURTIDE
Robert Wesolowski
Phase 1CC

View all 9 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →